Precautions while using Quizartinib

Quizartinib (Quizartinib) is a targeted therapy for patients with FLT3 internal tandem duplication (ITD)-positive acute myeloid leukemia (AML). However, this drug must be used with caution because it may cause QT prolongation, a condition that affects the heart rhythm. QT prolongation is an electrocardiogram sign in which a specific phase of the heart's electrical activity is prolonged. This can rarely lead to serious or even fatal fast heartbeats, irregular heartbeats, and other symptoms such as severe dizziness and fainting that require immediate medical attention.

Before using Quizartinib, patients must inform their doctor in detail about their health conditions and medication history. In particular, the use of Quizartinib is strictly prohibited in patients with certain heart conditions, such as long QT syndrome, fast heartbeats, or irregular heartbeats. At the same time, if the patient has a family history of heart disease, such as QT prolongation in the electrocardiogram or sudden cardiac death, the doctor should also be informed before use.

In addition, low levels of potassium or magnesium in the blood may also increase the risk of QT prolongation. Therefore, quizartinib should also be used with caution in patients who are taking medications that may cause potassium or magnesium loss (such as diuretics), or who have severe sweating, diarrhea, or vomiting. In this case, your doctor may recommend correcting the electrolyte imbalance before considering Quizartinib.

To reduce risk, doctors order blood tests (to monitor potassium and magnesium levels) and heart tests (such as an electrocardiogram) before and during treatment with Quizartinib. These inspections help identify and address any potential problems promptly. If patients experience symptoms such as fast, irregular heartbeat, severe dizziness or fainting during use, they should seek medical help immediately to ensure their own safety.

xa0

Reference materials:https://www.webmd.com/drugs/2/drug-187191/quizartinib-oral/details